Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acinetobacter baumannii capsular polysaccharide vaccine (K2/K3)
- Development stage
- Preclinical
- Lead developer
- Instituto de Salud Carlos III
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Acinetobacter baumannii capsular polysaccharide vaccine (K2/K3) is a preclinical bivalent vaccine candidate designed to prevent infections caused by multidrug-resistant Acinetobacter baumannii of the K2 and K3 capsular serotypes. Developed by researchers at the Instituto de Salud Carlos III (ISCIII) and the University of Notre Dame, the vaccine utilizes highly purified capsular polysaccharides (CPS) isolated from representative K2 and K3 strains. In preclinical murine models, intramuscular immunization with the K2 and K3 CPS antigens, with or without Alum adjuvant, elicited strong, specific IgG antibody responses (predominantly of the IgG2a subtype), demonstrating high immunogenicity and potential for active or passive immunization strategies against this critical nosocomial pathogen.
- Other names
- Acinetobacter baumannii K2/K3 CPS vaccineAcinetobacter baumannii K2/K3 capsular polysaccharide vaccine
02
Targets
A. baumannii (Acinetobacter baumannii)
Beyond the preview
Go deeper on Acinetobacter baumannii capsular polysaccharide vaccine (K2/K3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acinetobacter baumannii capsular polysaccharide vaccine (K2/K3).
Work on Acinetobacter baumannii capsular polysaccharide vaccine (K2/K3)? Claim this page to correct or add information. Claim this page